Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma

Prior treatment

• Allergic or intolerant to the investigational drug or its components;
• Received any experimental drug treatment within 4 weeks;
• Simultaneously suffering from other tumors, or having undergone anti-tumor treatment (including major surgery) in the past 4 weeks;
• Currently, there are poorly controlled heart diseases, such as heart function grade III or IV (NYAH classification),uncontrolled atrial fibrillation, unstable angina, and myocardial infarction within the 12 months prior to enrollment;
• Unable or unwilling to receive prophylactic antithrombotic therapy;

Other illness

• Suffering from mental illness;
• Accompanied by severe lung infection, skin and soft tissue infection, or urinary tract infection;
• Serious, uncontrolled medical disorders or active infections;

Other

• There was a serious thrombotic event before treatment;
• Researchers determine situations that are not suitable for inclusion.

• RRMM patients who have received 1-3 line treatment;
• Age above 18 years old, male or female not limited;
• ECOG score ≤ 2;
• Expected survival period is greater than 3 months;
• For female patients, (1) they have been menopausal for at least 24 months before the screening visit, or have undergone surgical contraception; (2) Women with fertility must have two negative urine HCG pregnancy tests within 72 hours before starting to take the study drug; For male patients must agree to absolute abstinence or effective barrier contraception throughout the entire study treatment period until 28 days after the last study drug treatment, and have no sperm donation behavior;
• The patient understands the purpose and steps of this trial, voluntarily participates in this trial, and signs a written informed consent form.